Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
95% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. RGEN: No Debt )
RGEN' s 10-Year Cash to Debt Range
Min: 3   Max: No Debt
Current: No Debt

Equity to Asset 0.89
RGEN's Equity to Asset is ranked higher than
91% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RGEN: 0.89 )
RGEN' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.98
Current: 0.89

0.5
0.98
Interest Coverage 457.46
RGEN's Interest Coverage is ranked higher than
56% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 457.46 )
RGEN' s 10-Year Interest Coverage Range
Min: 194.44   Max: 9999.99
Current: 457.46

194.44
9999.99
F-Score: 4
Z-Score: 32.08
M-Score: -2.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.29
RGEN's Operating margin (%) is ranked higher than
94% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. RGEN: 25.29 )
RGEN' s 10-Year Operating margin (%) Range
Min: -312.44   Max: 186.01
Current: 25.29

-312.44
186.01
Net-margin (%) 19.02
RGEN's Net-margin (%) is ranked higher than
93% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. RGEN: 19.02 )
RGEN' s 10-Year Net-margin (%) Range
Min: -224.93   Max: 192.3
Current: 19.02

-224.93
192.3
ROE (%) 10.95
RGEN's ROE (%) is ranked higher than
92% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. RGEN: 10.95 )
RGEN' s 10-Year ROE (%) Range
Min: -112.75   Max: 82.79
Current: 10.95

-112.75
82.79
ROA (%) 9.79
RGEN's ROA (%) is ranked higher than
93% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. RGEN: 9.79 )
RGEN' s 10-Year ROA (%) Range
Min: -56.79   Max: 75.79
Current: 9.79

-56.79
75.79
ROC (Joel Greenblatt) (%) 61.27
RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. RGEN: 61.27 )
RGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3120   Max: 1086.81
Current: 61.27

-3120
1086.81
Revenue Growth (%) 45.60
RGEN's Revenue Growth (%) is ranked higher than
96% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. RGEN: 45.60 )
RGEN' s 10-Year Revenue Growth (%) Range
Min: -48.5   Max: 45.6
Current: 45.6

-48.5
45.6
» RGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RGEN Guru Trades in Q4 2013

Joel Greenblatt 18,532 sh (New)
Jim Simons 563,400 sh (+61.39%)
» More
Q1 2014

RGEN Guru Trades in Q1 2014

Paul Tudor Jones 24,627 sh (New)
Joel Greenblatt 15,504 sh (-16.34%)
Jim Simons 465,993 sh (-17.29%)
» More
Q2 2014

RGEN Guru Trades in Q2 2014

Jim Simons 707,200 sh (+51.76%)
Paul Tudor Jones Sold Out
Joel Greenblatt 14,914 sh (-3.81%)
» More
Q3 2014

RGEN Guru Trades in Q3 2014

Jim Simons 855,504 sh (+20.97%)
Joel Greenblatt 12,871 sh (-13.7%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 New Buy0.01%$10 - $13.62 $ 22.8892%18532
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 63.20
RGEN's P/E(ttm) is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 63.20 )
RGEN' s 10-Year P/E(ttm) Range
Min: 3.19   Max: 762.86
Current: 63.2

3.19
762.86
P/B 6.50
RGEN's P/B is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. RGEN: 6.50 )
RGEN' s 10-Year P/B Range
Min: 1.42   Max: 7.26
Current: 6.5

1.42
7.26
P/S 12.00
RGEN's P/S is ranked higher than
80% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. RGEN: 12.00 )
RGEN' s 10-Year P/S Range
Min: 2.74   Max: 21.04
Current: 12

2.74
21.04
PFCF 37.60
RGEN's PFCF is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 37.60 )
RGEN' s 10-Year PFCF Range
Min: 3.18   Max: 379
Current: 37.6

3.18
379
EV-to-EBIT 43.80
RGEN's EV-to-EBIT is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 43.80 )
RGEN' s 10-Year EV-to-EBIT Range
Min: -2288.9   Max: 2812.1
Current: 43.8

-2288.9
2812.1
Shiller P/E 135.60
RGEN's Shiller P/E is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 135.60 )
RGEN' s 10-Year Shiller P/E Range
Min: 11.63   Max: 149.94
Current: 135.6

11.63
149.94
Current Ratio 7.23
RGEN's Current Ratio is ranked higher than
82% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. RGEN: 7.23 )
RGEN' s 10-Year Current Ratio Range
Min: 1.55   Max: 44.57
Current: 7.23

1.55
44.57
Quick Ratio 5.95
RGEN's Quick Ratio is ranked higher than
79% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. RGEN: 5.95 )
RGEN' s 10-Year Quick Ratio Range
Min: 1.4   Max: 43.88
Current: 5.95

1.4
43.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.80
RGEN's Price/Net Cash is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. RGEN: 18.80 )
RGEN' s 10-Year Price/Net Cash Range
Min: 1.7   Max: 25.53
Current: 18.8

1.7
25.53
Price/Net Current Asset Value 14.40
RGEN's Price/Net Current Asset Value is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. RGEN: 14.40 )
RGEN' s 10-Year Price/Net Current Asset Value Range
Min: 1.5   Max: 32.3
Current: 14.4

1.5
32.3
Price/Tangible Book 8.80
RGEN's Price/Tangible Book is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. RGEN: 8.80 )
RGEN' s 10-Year Price/Tangible Book Range
Min: 0.94   Max: 14.59
Current: 8.8

0.94
14.59
Price/DCF (Projected) 3.60
RGEN's Price/DCF (Projected) is ranked higher than
94% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 3.60 )
RGEN' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 3.74
Current: 3.6

0.69
3.74
Price/Median PS Value 1.90
RGEN's Price/Median PS Value is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. RGEN: 1.90 )
RGEN' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 9.5
Current: 1.9

0.18
9.5
Price/Graham Number 5.00
RGEN's Price/Graham Number is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 5.00 )
RGEN' s 10-Year Price/Graham Number Range
Min: 0.54   Max: 6.25
Current: 5

0.54
6.25
Earnings Yield (Greenblatt) 2.30
RGEN's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. RGEN: 2.30 )
RGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 9.7
Current: 2.3

0.1
9.7
Forward Rate of Return (Yacktman) 1.06
RGEN's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. RGEN: 1.06 )
RGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -40.3   Max: 36.8
Current: 1.06

-40.3
36.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RGN.Germany
Repligen Corp was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies. It is also engaged in the manufacture of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of biomanufacturing technologies, it has developed and currently markets a series of OPUS or Open-Platform, User-Specified chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures seven forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. On December 28, 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. On January 21, 2014, it also out-licensed its histone deacetylase inhibitor portfolio which includes the Friedreich's ataxia program, to BioMarin Pharmaceuticals Inc., or BioMarin. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. It sells its bioprocessing products through direct sales force to partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and to distributors in certain foreign markets.
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Reports First Quarter Fiscal Year 2010 Financial Results Aug 06 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 


More From Other Websites
REPLIGEN CORP Financials Nov 14 2014
Repligen to Present at Stifel Healthcare Conference 2014 Nov 12 2014
Repligen to Present at Stifel Healthcare Conference 2014 Nov 12 2014
10-Q for Repligen Corp. Nov 10 2014
REPLIGEN CORP Files SEC form 10-Q, Quarterly Report Nov 07 2014
Repligen posts 3Q profit Nov 06 2014
Repligen posts 3Q profit Nov 06 2014
Repligen Reports Third Quarter 2014 Financial Results Nov 06 2014
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
Repligen Reports Third Quarter 2014 Financial Results Nov 06 2014
Q3 2014 Repligen Corp Earnings Release - Before Market Open Nov 06 2014
Repligen to Present at Stephens Inc. Fall Investment Conference Nov 05 2014
Repligen to Report Third Quarter 2014 Financial Results Oct 23 2014
Repligen to Report Third Quarter 2014 Financial Results Oct 23 2014
Repligen to Host Investor & Analyst Event on October 16 Oct 10 2014
REPLIGEN CORP Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial... Aug 18 2014
REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 11 2014
REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 15 2014
Repligen (RGEN) Shares March Higher, Can It Continue? Jun 27 2014
REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK